{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Coagulation+Disorder&page=7",
    "query": {
      "condition": "Blood Coagulation Disorder",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 855,
    "total_pages": 86,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Coagulation+Disorder&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Coagulation+Disorder&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T01:01:17.488Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01880047",
      "title": "Safety and Efficacy of Eltrombopag at Escalated Doses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia",
        "Platelet Disorder"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2013-02",
      "completion_date": "2017-10-16",
      "has_results": true,
      "last_update_posted_date": "2019-06-11",
      "last_synced_at": "2026-10-24T01:01:17.488Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01880047"
    },
    {
      "nct_id": "NCT01971684",
      "title": "ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Second Line ITP agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 120,
      "start_date": "2013-08",
      "completion_date": "2017-04",
      "has_results": false,
      "last_update_posted_date": "2020-05-21",
      "last_synced_at": "2026-10-24T01:01:17.488Z",
      "location_count": 26,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Oakland, California + 22 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01971684"
    },
    {
      "nct_id": "NCT07007962",
      "title": "Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "rilzabrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-10-24",
      "completion_date": "2028-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-24T01:01:17.488Z",
      "location_count": 12,
      "location_summary": "Clovis, California • Los Angeles, California • New Orleans, Louisiana + 8 more",
      "locations": [
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07007962"
    },
    {
      "nct_id": "NCT01619046",
      "title": "Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "GreenGene™ F and an approved recombinant Factor VIII product",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GreenGene™ F",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Green Cross Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2013-03",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2014-07-03",
      "last_synced_at": "2026-10-24T01:01:17.488Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Torrance, California + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01619046"
    },
    {
      "nct_id": "NCT05911763",
      "title": "A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Efanesoctocog Alfa BIVV001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 200,
      "start_date": "2023-06-30",
      "completion_date": "2030-09-17",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-24T01:01:17.488Z",
      "location_count": 28,
      "location_summary": "Gilbert, Arizona • Loma Linda, California • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05911763"
    },
    {
      "nct_id": "NCT06291415",
      "title": "The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Immune Thrombocytopenia",
        "Blood Platelet Disorder",
        "Hematologic Diseases",
        "Purpura, Thrombocytopenic",
        "Purpura",
        "Blood Coagulation Disorder",
        "Thrombotic Microangiopathies",
        "Hemorrhagic Disorders",
        "Autoimmune Diseases",
        "Immune System Diseases",
        "Hemorrhage",
        "Pathologic Processes",
        "Skin Manifestations",
        "Thrombocytopenia",
        "Purpura, Thrombocytopenic, Idiopathic",
        "Primary Immune Thrombocytopenia",
        "ITP - Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "HMPL-523",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-04-02",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-10-24T01:01:17.488Z",
      "location_count": 10,
      "location_summary": "Irvine, California • Georgetown, Delaware • Bethesda, Maryland + 7 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Georgetown",
          "state": "Delaware"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Farmington",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06291415"
    },
    {
      "nct_id": "NCT00618098",
      "title": "Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Reversal of Anticoagulant Treatment"
      ],
      "interventions": [
        {
          "name": "Octaplex (human prothrombin complex concentrate)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fresh frozen plasma",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2008-05",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-10-24T01:01:17.488Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00618098"
    },
    {
      "nct_id": "NCT06218628",
      "title": "Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis",
        "Chronic Myelomonocytic Leukemia",
        "Polycythemia Vera",
        "Essential Thrombocytosis"
      ],
      "interventions": [
        {
          "name": "Talazoparib",
          "type": "DRUG"
        },
        {
          "name": "pacritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2024-04-05",
      "completion_date": "2030-08-27",
      "has_results": false,
      "last_update_posted_date": "2024-05-03",
      "last_synced_at": "2026-10-24T01:01:17.488Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06218628"
    },
    {
      "nct_id": "NCT01931644",
      "title": "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "All Diagnosed Health Conditions",
        "ADD/ADHD",
        "Alopecia Areata",
        "Ankylosing Spondylitis",
        "Asthma",
        "Atopic Dermatitis Eczema",
        "Beta Thalassemia",
        "Bipolar Disorder",
        "Breast Cancer",
        "Celiac Disease",
        "Cervical Cancer",
        "Chronic Inflammatory Demyelinating Polyneuropathy",
        "Chronic Kidney Diseases",
        "Chronic Obstructive Pulmonary Disease",
        "Colon Cancer",
        "Colorectal Cancer",
        "Crohn's Disease",
        "Cystic Fibrosis",
        "Depression",
        "Diabetes Mellitus",
        "Duchenne Muscular Dystrophy",
        "Endometriosis",
        "Epilepsy",
        "Facioscapulohumeral Muscular Dystrophy",
        "G6PD Deficiency",
        "General Anxiety Disorder",
        "Hepatitis B",
        "Hereditary Hemorrhagic Telangiectasia",
        "HIV/AIDS",
        "Human Papilloma Virus",
        "Huntington's Disease",
        "Idiopathic Thrombocytopenic Purpura",
        "Insomnia",
        "Kidney Cancer",
        "Leukemia",
        "Lung Cancer",
        "Lupus Nephritis",
        "Lymphoma",
        "Melanoma",
        "Multiple Myeloma",
        "Multiple Sclerosis",
        "Myositis",
        "Myotonic Dystrophy",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Parkinson's Disease",
        "Polycystic Kidney Diseases",
        "Prostate Cancer",
        "Psoriasis",
        "Psoriatic Arthritis",
        "Rosacea",
        "Scleroderma",
        "Sickle Cell Anemia",
        "Sickle Cell Trait",
        "Sjogren's Syndrome",
        "Skin Cancer",
        "Spinal Muscular Atrophy",
        "Systemic Lupus Erythematosus",
        "Thrombotic Thrombocytopenic Purpura",
        "Trisomy 21",
        "Ulcerative Colitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sanguine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 17667,
      "start_date": "2013-07",
      "completion_date": "2024-04",
      "has_results": false,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-10-24T01:01:17.488Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01931644"
    },
    {
      "nct_id": "NCT01713855",
      "title": "Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Idiopathic Thrombocytopenic Purpura",
        "Immune Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Inactivated Trivalent Influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Neufeld, Ellis J, MD, PhD",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "18 Months to 18 Years"
      },
      "enrollment_count": 10,
      "start_date": "2004-10",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2012-10-25",
      "last_synced_at": "2026-10-24T01:01:17.488Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01713855"
    }
  ]
}